Summary We report a Li-Fraumeni syndrome family in which we have detected a splice acceptor mutation in intron 3 of TP53. The mutation affects one of the invariant residues at the splice acceptor site. as a result of which two aberrant transcripts are produced. A child with Wilms tumour aged 3 years in this family was shown not to be a mutation carrier. 
disorder in which there is greatly increased cancer susceptibilitN.
LFS is characterized bv bone and soft-tissue sarcomas. earlv -onset breast cancer. brain tumours. leukaemia and childhood adrenocortical tumours (Li et al. 1988) . and a proportion of LFS families show germline transmission of a mutant TP53 gene. We hav-e identified an LFS familv in which there is a number of tumours typical of the syndrome. and we have screened for a germline TP53 mutation. The identification of a TP53 mutation in this familv (Varlev et al. 1997 ) has allowved us to exclude a number of cancer-affected indi' iduals in the familv from linkage to a germline TP53 mutation. includinc a child A ith Wilms' tumour.
PATIENTS AND METHODS
The pedigree of family 86 is sho'a-n in Figure 1 . There is a high incidence of cancer in the family. which conforms to the definition of classic LFS (Li et al. 1988 ). Blood samples were obtained from V-3 (chondroblastic osteosarcoma of the humerus aged 15) and his parents. and DNA from V-3 and IV-5 A ere screened for a germ-ine TP53 mutation by direct sequencing of all exons as described previously (Varley et al. 1997 (Hollstein et al. 1996) found three intron 3 splice acceptor mutations. none of hich is identical to that reported in this present study (Takahashi et al. 1990: Suzuki et Although the mutation reported in family 86 affects one of the invariant residues of the splice acceptor sequence and is. therefore. predicted to completely abolish correct splicing from the mutant allele. we felt it necessary to demonstrate abnormal splicing before offering the family a predictive test. Although we may have been overcautious in this case. it is strongly recommended that novel mutations. or those in which the functional significance is unclear. are evaluated as fully as possible before being used in predictive testing. The evaluation may take the form of testing in one of the functional assays currently available or. in the case of splicing mutations. analysis of the transcripts produced.
